U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07376629) titled 'A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC' on Jan. 13.
Brief Summary: This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of HB0025 administered with chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
Study Start Date: Aug. 14, 2025
Study Type: INTERVENTIONAL
Condition:
TNBC
Intervention:
DRUG: HB0025 20 mg/kg plus nab-paclitaxel
HB0025 20 mg/kg
DRUG: HB0025 10 mg/kg plus nab-paclitaxel
HB0025 10 mg/kg
R...